Product Description
Dimethyl Sulfoxide is a highly polar organic liquid that is used widely as a chemical solvent and a free radical scavenger. It shows a range of pharmacological activity including analgesia and anti-inflammation. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect cells and tissue during cryopreservation and has been used to treat extravasation damage caused by anthracycline-based chemotherapy. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dimethyl-sulfoxide)
Mechanisms of Action: Free Radical Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Egypt | Estonia | Germany | Greece | Hong Kong | Hungary | Japan | Jordan | Korea | Russia | Singapore | Spain | Taiwan | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: HERMAL Kurt Herrmann &OHG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Italy
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Sarcoma
Phase 2: Keratoconjunctivitis Sicca
Phase 1: Melanoma|Skin Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12624000310561 | P1 |
Not yet recruiting |
Melanoma|Skin Cancer |
2025-07-30 |
|
| NGF0123 | P2 |
Recruiting |
Keratoconjunctivitis Sicca |
2025-03-31 |
|
| MULTISARC | P3 |
Active, not recruiting |
Sarcoma |
2023-12-31 |